Abstract:Innate immune responses recognizing pathogen associated molecular patterns play important roles in adaptive immunity. As such, ligands which mimic the conserved products of microbial and activate innate immunity are widely used as adjuvants for vaccines. Synthetic single strand oligodeoxynucleotides (ODNs) containing unmethylated cytosine-guanine (CpG) motifs which bind Toll-like receptor 9 (TLR9) are powerful molecular adjuvants, potentiating both humoral and cellular responses. However, CpG ODN's in vitro potency has not been translated to in vivo settings primarily due to issues associated with delivery and toxicity. A major challenge in clinical application of CpG ODN is the efficient delivery to lymph nodes, the anatomic sites where all the immune responses are initiated. Targeting CpG to the key antigen presenting cells (APC) is essential for its application as a vaccine adjuvant, as it not only enhances CpG's efficacy, but also greatly reduces the systemic toxicity. We recently discovered an "albumin-hitchhiking" approach by which CpG ODNs were conjugated to a lipophilic lipid tail and follow subcutaneous injection, accumulated in lymph nodes by binding and transporting with endogenous albumin. This molecular approach targets CpG to antigen presenting cells in the draining lymph nodes via an endogenous albumin-mediated mechanism and simultaneously improves both the efficacy and safety of CpG as a vaccine adjuvant. Since CpG ODNs can be divided into structurally distinct classes, and each class of CpG ODN activates different types of immune cells and triggers different types of immunostimulatory activities, it is important to thoroughly evaluate the efficacy of this "albumin-hitchhiking" strategy in each class of CpG. Here we compare the immunostimulatory activities of three classes of lipid conjugated CpG ODNs in vitro and in vivo. Three representative sequences of lipid modified CpG ODNs were synthesized and their stimulatory effects as a vaccine adjuvant were evaluated. Our results showed that in vitro, lipid modified class A CpG exhibited enhanced stimulatory activities toward TLR transfected reporter cells or bone-marrow derived dendritic cells, whereas lipid-modification of class B or C CpG reduces the activation of TLR9 by 2-3 fold, as compared with unmodified class B and class C CpG, respectively. However, in vivo coadministration of ovalbumin (OVA) protein antigen mixed with lipid-conjugated class B or C CpG ODNs, but not class A CpGs induced dramatically increased OVA-specific humoral and cytotoxic CD8+ T cells responses compared with OVA mixed with unmodified CpGs. Further, lipid-modification greatly reduces the toxicity associated with CpG by minimizing the systemic dissemination. Taken together, these results demonstrated that amphiphilic modification of three classes of CpG motifs differentially affected and modulated the immunostimulatory activities in vitro and in vivo. Our study highlights the importance of in vivo lymph node targeting of CpG ODNs in fulfilling their use as vaccine adjuvants, providing implications for the rational design of molecular adjuvant for subunit vaccines.

Potent CpG Oligonucleotides Containing Phosphodiester Linkages: in Vitro and in Vivo Immunostimulatory Properties.

Enhanced Immunostimulatory Activity of a Cytosine-Phosphate-Guanosine Immunomodulator by the Assembly of Polymer DNA Wires and Spheres

Enhancing Immunogenicity by CpG DNA.

CpG-PEG Conjugates and Their Immune Modulating Effects after Systemic Administration

Structure-efficacy Relationships of Immunostimulatory Activity of CpG- Containing Oligodeoxynucleotides on Mouse Spleen Cells

Immunostimulatory Properties of Lipid Modified CpG Oligonucleotides

Immunogenicity and Safety of Liposome-Vaccine Encapsulating Hepatitis B Surface Antigen and Phosphodiester CpG Oligodeoxynucleotides

The Effects of CpG-C Oligodeoxynucleotides on Innate Immune Responses in Eriocheir Sinensis (H. Milne-Edwards, 1853)

Non-CpG Oligonucleotides Exert Adjuvant Effects by Enhancing Cognate B Cell-T Cell Interactions, Leading to B Cell Activation, Differentiation, and Isotype Switching

Synthetic oligodeoxynucleotides containing deoxycytidyl-deoxyguanosine dinucleotides (CpG ODNs) and modified analogs as novel anticancer therapeutics.

The Immunostimulatory Effects of CpG Oligonucleotide on Human Peripheral Blood B Lymphocyte

The effects of CpG DNA on HMGB1 release by murine macrophage cell lines.

Cytosine-phosphate-guanine oligodeoxynucleotides containing GACGTT motifs enhance the immune responses elicited by keyhole limpet hemocyanin antigen in dairy cattle

Synthetic Oligodeoxynucleotide Containing CpG Motifs Enhancing the Production of Th1 Cytokines Induced by Dermatophagoides Farinae Allergens in Vitro

Potent Anti-Tumor Immunostimulatory Biocompatible Nanohydrogel Made from DNA

Potent Antigen-specific Immune Responses Stimulated by Codelivery of CpG ODN and Antigens in Degradable Microparticles

Anti-neoplasm and immuno-modification effect of novel CpG oligodeoxynucleotides in mice

A Comparative Study of the Antigen‐specific Immune Response Induced by Co‐delivery of CpG ODN and Antigen Using Fusion Molecules or Biodegradable Microparticles**xue‐qing Zhang and Christopher E. Dahle Contributed Equally to This Work.

Homotypic Targeting of Immunomodulatory Nanoparticles for Enhanced Peripheral and Central Immunity

Modulating the Cellular Immune Response of Oligonucleotides by Brush Polymer-Assisted Compaction.

Organelle-Specific Triggered Release of Immunostimulatory Oligonucleotides from Intrinsically Coordinated DNA-Metal-Organic Frameworks with Soluble Exoskeleton